Fostemsavir + Cobicistat = Unknown or no reaction

Effect on Concentration

Fostemsavir
Increase
Applies within class?
No
Cobicistat
Unknown
Applies within class?
No

Pharmacologic Effects

Fostemsavir
Effect
N/A
Applies within class?
No
Cobicistat
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 18-Jul-2018

Summary

The authors state that no dose modification is required when co-administering fostemsavir with COBI based on the exposure-safety profile of fostemsavir to date.

Sources

Fostemsavir vs cobicistat ^

Study Design

An open-label, single-sequence, pharmacokinetic (PK) study was conducted to evaluate potential drug-drug interactions when fostemsavir (formerly known as BMS-663068), a pro-drug of BMS-626529, is co-administered with cobicistat (COBI) in 16 healthy subjects.Fostemsavir 600 mg was administered BID on days 1-4, followed by fostemsavir (600 mg) BID with COBI (150 mg) daily on days 5-14.

Study Results

Co-administration of fostemsavir with COBI increased active metabolite BMS-626529 Cmax, AUCtau, and C12geometric mean ratios (GMRs; 90% CI) by 71%, 93%, and 136%, respectively. These changes in PK parameters were not considered clinically meaningful.PK parameters for COBI were not reported.

Study Conclusions

References

B Vakkalaggadda, A Griffies, M Hesney, et al. Hiv-1 attachment inhibitor prodrug bms-663068: interactions with cobicistat and darunavir/cobicistat. Joint 55th Interscience Conference On Antimicrobial Agents And Chemotherapy Meeting. San Diego, CA. ; 2016.